-
1.发明授权Soluble lymphotoxin-&bgr; receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease 有权可溶性淋巴毒素-β受体作为治疗TH-1细胞相关自身免疫疾病的治疗剂公开(公告)号：US06669941B1
公开(公告)日：2003-12-30
申请号：US09303262
申请日：1999-04-30
IPC分类号： A01N3800
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-&bgr; receptor blocking agents”, which block lymphotoxin-&bgr; receptor signalling. Lymphotoxin-&bgr; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&bgr; receptor extracellular domain that act as lymphotoxin-&bgr; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&bgr; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&bgr; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&bgr; receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导。 淋巴毒素-β受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体细胞外结构域的可溶性形式。 本发明还涉及针对作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体或其配体表面淋巴毒素的抗体的用途。 提供了一种选择可溶性受体，抗体和阻断LT-β受体信号传导的其他试剂的筛选方法。
-
2.发明授权Soluble lymphotoxin-&bgr; receptors as therapeutic agents for the treatment of immunological disease 失效可溶性淋巴毒素-β受体作为治疗免疫疾病的治疗剂公开(公告)号：US06403087B1
公开(公告)日：2002-06-11
申请号：US09000166
申请日：1998-06-08
IPC分类号： A61K39395
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-&bgr; receptor blocking agents”, which block lymphotoxin-&bgr; receptor signalling. Lymphotoxin-&bgr; receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-&bgr; receptor extracellular domain that act as lymphotoxin-&bgr; receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-&bgr; receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-&bgr; receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-&bgr; receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导。 淋巴毒素-β受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体细胞外结构域的可溶性形式。 本发明还涉及针对作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体或其配体表面淋巴毒素的抗体的用途。 提供了一种选择可溶性受体，抗体和阻断LT-β受体信号传导的其他试剂的筛选方法。
-
3.发明授权Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling 有权可溶性淋巴毒素 受体融合蛋白和抑制淋巴毒素和受体信号传导的方法公开(公告)号：US07951371B2
公开(公告)日：2011-05-31
申请号：US11982415
申请日：2007-10-31
IPC分类号： C07K19/00 , C07K14/715 , A61K38/17 , C07K14/52
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β.receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素 - 受体阻断剂”的组合物和方法，其阻断淋巴毒素 - 受体信号。 淋巴毒素 受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素 - bgr的淋巴毒素 - 受体细胞外结构域的可溶性形式。 受体阻断剂。 本发明还涉及针对淋巴毒素 - 抗体的抗体的用途。 受体或其配体，表面淋巴毒素，作为淋巴毒素 - 受体阻断剂。 用于选择可溶性受体，抗体和阻断LT-和bgr的其它试剂的新型筛选方法; 提供受体信号。
-
4.发明申请SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING 有权可溶性的LYMPHOTOXIN-BETA受体融合蛋白和抑制LYMPHOTOXINβ受体信号的方法公开(公告)号：US20110046073A1
公开(公告)日：2011-02-24
申请号：US11982415
申请日：2007-10-31
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β.receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β.receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素 - 受体阻断剂”的组合物和方法，其阻断淋巴毒素 - 受体信号。 淋巴毒素 受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素 - bgr的淋巴毒素 - 受体细胞外结构域的可溶性形式。 受体阻断剂。 本发明还涉及针对作为淋巴毒素 - 蛋白的淋巴毒素 - 受体或其配体表面淋巴毒素的抗体的用途。 受体阻断剂。 用于选择可溶性受体，抗体和阻断LT-和bgr的其它试剂的新型筛选方法; 提供受体信号。
-
5.发明授权Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease 失效可溶性淋巴毒素-β受体和抗淋巴毒素受体和配体抗体作为治疗免疫疾病的治疗剂
公开(公告)号：US5925351A
公开(公告)日：1999-07-20
申请号：US505606
申请日：1995-07-21
IPC分类号： A61K38/00 , G01N33/566 , A61K31/00 , A61K38/17 , A61K38/19 , A61K39/00 , A61K39/395 , A61P1/00 , A61P1/04 , A61P3/00 , A61P3/10 , A61P15/00 , A61P17/00 , A61P17/06 , A61P21/00 , A61P25/00 , A61P27/00 , A61P27/02 , A61P29/00 , A61P37/00 , A61P37/02 , A61P37/06 , C07K14/715 , C07K16/24 , C07K16/28 , C12N15/02 , C12P21/08 , G01N33/00 , G01N33/577 , G01N33/68 , A61K38/16 , C07K16/00
CPC分类号： C07K14/7151 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , A61K2039/505 , A61K38/00 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising "lymphotoxin-.beta. receptor blocking agents", which block lymphotoxin-.beta. receptor signalling. Lymphotoxin-.beta. receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-.beta. receptor extracellular domain that act as lymphotoxin-.beta. receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-.beta. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-.beta. receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-.beta. receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导。 淋巴毒素-β受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体细胞外结构域的可溶形式。 本发明还涉及针对作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体或其配体表面淋巴毒素的抗体的用途。 提供了一种筛选可溶性受体，抗体和阻断LT-β受体信号传导的其他试剂的筛选方法。
-
6.发明授权Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders 有权抑制TH1细胞相关疾病中淋巴毒素-β受体信号传导的方法公开(公告)号：US08455445B2
公开(公告)日：2013-06-04
申请号：US13037092
申请日：2011-02-28
IPC分类号： A61K38/16 , A61P19/02 , C07K19/00 , C07K14/715
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导。 淋巴毒素-β受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体细胞外结构域的可溶性形式。 本发明还涉及针对作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体或其配体表面淋巴毒素的抗体的用途。 提供了一种选择可溶性受体，抗体和阻断LT-β受体信号传导的其他试剂的筛选方法。
-
公开(公告)号：US07427403B2
公开(公告)日：2008-09-23
申请号：US10077406
申请日：2002-02-15
IPC分类号： A61K38/16 , A61K39/395 , C07K14/715 , C07K16/28
CPC分类号： C07K14/7151 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K16/241 , C07K16/2866 , C07K16/2878 , C07K2317/74 , C07K2319/00 , C07K2319/30 , Y10S514/825 , Y10S514/866 , Y10S514/885 , Y10S514/903 , Y10S930/143
摘要： This invention relates to compositions and methods comprising “lymphotoxin-β receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
摘要翻译： 本发明涉及包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号传导。 淋巴毒素-β受体阻断剂可用于治疗淋巴细胞介导的免疫疾病，更具体地，用于抑制Th1细胞介导的免疫应答。 本发明涉及作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体细胞外结构域的可溶性形式。 本发明还涉及针对作为淋巴毒素-β受体阻断剂的淋巴毒素-β受体或其配体表面淋巴毒素的抗体的用途。 提供了一种选择可溶性受体，抗体和阻断LT-β受体信号传导的其他试剂的筛选方法。
-
8.发明授权Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases 有权可溶性淋巴毒素-β受体和抗淋巴毒素受体和配体抗体作为治疗免疫疾病的治疗剂公开(公告)号：US08287874B2
公开(公告)日：2012-10-16
申请号：US12813029
申请日：2010-06-10
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7151 , C07K16/241 , C07K16/2878 , C07K2319/00 , Y02A50/414
摘要： Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
摘要翻译： 组合物和方法，包括淋巴毒素 - 阻断淋巴细胞生成素的受体阻断剂 受体信号传导，并且可用于改变免疫疾病，特别是抗体介导的免疫应答。
-
9.发明授权Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases 有权可溶性淋巴毒素-β受体和抗淋巴毒素受体和配体抗体作为治疗免疫疾病的治疗剂公开(公告)号：US07744891B2
公开(公告)日：2010-06-29
申请号：US11891847
申请日：2007-08-13
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7151 , C07K16/241 , C07K16/2878 , C07K2319/00 , Y02A50/414
摘要： Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
摘要翻译： 组合物和方法包括“淋巴毒素 - 受体阻断剂“，其阻断淋巴毒素 - 受体信号传导，并且可用于改变免疫疾病，特别是抗体介导的免疫应答。
-
10.发明授权Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases 有权使用淋巴毒素-β受体阻断剂治疗抗体介导的免疫疾病公开(公告)号：US07255854B1
公开(公告)日：2007-08-14
申请号：US09299139
申请日：1999-04-23
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7151 , C07K16/241 , C07K16/2878 , C07K2319/00 , Y02A50/414
摘要： Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
摘要翻译： 包含“淋巴毒素-β受体阻断剂”的组合物和方法，其阻断淋巴毒素-β受体信号并且可用于改变免疫疾病，特别是抗体介导的免疫应答。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.03 秒)
